Optimize Ophthalmology Express Scripts Integration for Faster Patient Care

Klivira offers a robust ophthalmology Express Scripts integration, automating prior authorizations for high-volume treatments like anti-VEGF injections and premium IOLs, ensuring faster approval times and reduced administrative burden.

Revenue cycle directors and prior authorization coordinators in ophthalmology practices face unique challenges managing PBM-driven PAs, particularly for chronic, high-cost therapies. Navigating Express Scripts' specific requirements for medical and pharmacy benefits demands precision and efficiency to maintain patient access to critical eye care and optimize practice revenue.

The Critical Need for Ophthalmology Express Scripts Integration

Ophthalmology practices frequently encounter Express Scripts prior authorization requirements for both pharmacy and medical benefits, especially for specialty drugs and advanced procedures. This integration is crucial for managing the complex interplay between clinical necessity, payer policy, and the chronic nature of many eye conditions, directly impacting patient access and practice financial health.

High-Volume Ophthalmology PAs Managed via Express Scripts

  • Anti-VEGF intravitreal injections (e.g., Aflibercept, Ranibizumab, Faricimab) for wet AMD, DME, RVO.
  • Cataract surgery with premium intraocular lenses (IOLs) or specific lens technology.
  • Glaucoma surgical procedures, including micro-invasive glaucoma surgery (MIGS).
  • Corneal cross-linking for keratoconus.
  • Medically necessary oculoplastic procedures like blepharoplasty for visual field impairment.
  • Specialty ophthalmic drops and compounded medications.

Streamlining Documentation for Express Scripts Ophthalmology PAs

Adhering to Express Scripts' specific documentation requirements, often informed by AAO Preferred Practice Patterns, is paramount. Klivira's platform facilitates the collection and submission of critical data points such as OCT findings, visual acuity, prior treatment responses for anti-VEGF cycles, and visual field tests for oculoplastic procedures, reducing common denial triggers like biosimilar substitution issues or cosmetic-vs-medical disputes.

Addressing Chronic Treatment Workflows and PBM Policies

The chronic nature of conditions requiring anti-VEGF injections means ongoing re-authorizations are a core operational task for retina practices. Klivira's ophthalmology Express Scripts integration automates the periodic re-authorization process, ensuring timely submissions and compliance with payer-specific step therapy requirements for biosimilars, minimizing treatment delays and administrative burden associated with high-volume, repetitive PA cycles.

Klivira's Solution for Express Scripts Ophthalmology PA Automation

Klivira integrates directly with EMR systems via SMART on FHIR and connects with Express Scripts via X12 278 and ePA channels, including NCPDP SCRIPT where applicable. Our platform leverages AAO-guideline-aware logic to automate anti-VEGF re-authorization workflows, manage biosimilar substitution routing, and provide intelligent support for cosmetic-vs-medical determinations in oculoplastics, significantly reducing manual effort and improving turnaround times.

Frequently asked questions

How does Klivira handle anti-VEGF re-authorizations with Express Scripts?

Klivira automates the re-authorization process for chronic anti-VEGF injection cycles by integrating with your EMR to pull necessary clinical documentation like OCT findings and prior treatment responses. This data is then formatted and submitted to Express Scripts according to their specific policy requirements, often via ePA or X12 278, reducing manual effort for ongoing treatments.

Can Klivira help with biosimilar substitution requirements from Express Scripts?

Yes, Klivira's platform incorporates payer-specific policy libraries, including those from Express Scripts, to identify when biosimilar substitution is required. It helps route authorizations correctly, alerting staff to potential denials for brand-name drugs when a biosimilar is mandated, thus streamlining compliance and preventing unnecessary denials.

What EMR data does Klivira use for ophthalmology PAs with Express Scripts?

Klivira integrates with your EMR to extract relevant clinical data for ophthalmology PAs. This includes diagnosis confirmations, visual acuity, OCT imaging results, fluorescein angiography reports, visual field tests, IOP documentation, and prior medication trials, all critical for substantiating medical necessity to Express Scripts.

Does Klivira support premium IOL prior authorizations for Express Scripts?

Yes, Klivira supports the prior authorization process for premium IOLs. While standard cataract surgery rarely requires PA, premium lens upgrades or specific specialty lens technologies often do. Klivira assists in compiling the necessary documentation, including patient acknowledgment of out-of-pocket costs and medical necessity justifications, for submission to Express Scripts.

How does Klivira address the 'cosmetic vs. medical' challenge for oculoplastics with Express Scripts?

Klivira incorporates logic to assist with the cosmetic-vs-medical determination for oculoplastic procedures like blepharoplasty. The platform guides staff to gather and submit required documentation, such as visual field tests demonstrating functional impairment and photographs, to support medical necessity claims to Express Scripts, minimizing denials based on cosmetic intent.

Related coverage

Other ophthalmology prior auth workflows

Ready to automate this workflow for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo